AMENDMENT

In the Claims:

The following listing of claims replaces all previous listings or versions thereof:

1. (Canceled)

2. (Currently amended) A pharmaceutical composition comprising at least one digitalis glycoside and an amorphous cyclodextrin, wherein the at least one digitalis glycoside includes oleandrin, wherein the ratio by weight of digitalis glycoside to amorphous cyclodextrin is in the range of from between 1:100 to 1:20.

3. (Original) The composition of claim 2, wherein the pharmaceutical composition comprises one or more excipients.

4. (Original) The composition of claim 2, wherein pharmaceutical composition comprises one or more pharmaceutically acceptable antioxidants.

5. (Original) The composition of claim 2, wherein the pharmaceutical composition comprises one or more pharmaceutically acceptable preservatives.

6. (Original) The composition of claim 2, wherein the pharmaceutical composition comprises one or more pharmaceutically acceptable buffering agents.

7. (Original) The composition of claim 2, wherein the pharmaceutical composition comprises one or more pharmaceutically acceptable polysaccharides.

8. (Original) The composition of claim 3, wherein the said excipients comprises mannitol, sorbitol, fructose, glucose, lactose, sucrose, trehalose or any other water soluble sugar.

9. (Original) The composition of claim 4, wherein the said antioxidants comprise ascorbic acid, sodium ascorbate, sodium bisulfate, sodium metabisulfate, curcumin, curcumin derivatives, ursolic acid, resveratrol, resveratrol derivatives, alpha-lipoic acid or monothio glycerol.

10. (Original) The composition of claim 5, wherein the said preservatives comprise a methylparaben, methylparaben sodium, propylparaben, propylparaben sodium, benzalkonium chloride, or benzthonium chloride.

11. (Original) The composition of claim 6, wherein the said buffering agents comprise monobasic and dibasic sodium phosphate, sodium benzoate, potassium benzoate, sodium citrate, sodium acetate or sodium tartrate.

12. (Original) The composition of claim 7, wherein the polysaccharides comprise dextran sulfate, pectin, modified pectin, insoluble 1,3- β-D glucan, micronized 1,3- β-D glucan, soluble 1,3- β-D glucan, phosphorylated 1,3- β-D glucan, aminated 1,3- β-D glucan or carboxymethylated 1,3- β-D glucan, sulfated 1,3- β-D glucan.

13. (Previously presented) The composition of claim 2, wherein the digitalis glycoside further comprises one or more of , neriifolin, odoroside A or H, ouabain (G-strophantin), cymarin, sarmentocymarin, periplocymarin, K-strophantin, thevetin A, cerberin, peruvoside, thevetosin, thevetin B, tanghinin, deacetyltanghinin, echujin, hongheloside G, honghelin, periplocin, strophantidol, nigrescin. uzarin, calotropin, cheiroside A, cheirotoxin, euonoside, euobioside, euomonoside, lancetoxin A and B, kalanchoside, bryotoxin A-C, bryophyllin B, cotiledoside, tyledoside A-D, F and G, orbicuside A-C, alloglaucotoxin, corotoxin, coroglaucin, glaucorin, scillarene A and B, scilliroside, scilliacinoside, scilliglaucoside, scilliglaucosidin, scillirosidin, scillirubrosidin, scillirubroside, proscillaridin A, methyl-proscillaridin A, rubelin, convalloside, convallatoxin, bovoside A, glucobovoside A, bovoruboside, antiarin A, helleborin, hellebrin, adonidin, adonin, adonitoxin, thesiuside, digitoxin, gitoxin, gitalin, digoxin, F-gitonin, digitonin, lanatoside A-C, bufotalin, bufotalinin, bufotalidin, pseudobufotalin, acetyl-digitoxin, acetyl-oleandrin, beta-methyldigoxin or alpha-methyldigoxin.

14. – 19. (Canceled)

20. (Original) The composition of claim 2 wherein said amorphous cyclodextrin has a degree of substitution of 2 to 7.

21. (Canceled).

22. (Previously presented) A process for preparing a pharmaceutical composition comprising admixing at least one digitalis glycoside, wherein one of said at least one digitalis glycosides is oleandrin, with an amorphous cyclodextrin and rendering said composition pharmaceutically acceptable.

23. (Original) The process of claim 22, wherein the composition is rendered sterile by filtration.

24. (Original) The process of claim 22, wherein the composition is freeze-dried or lyophilized.

25. (Previously presented) A method of treating a cell proliferative disease in a subject comprising administering an amount of the composition of claim 2 that is effective to treat the cell proliferative disease, wherein the proliferative disease is cancer.

26. (Original) The method of claim 25, wherein the subject is a human subject.

27. (Original) The method of claim 25, wherein the composition comprises the digitalis glycoside at a concentration of from 0.01 mg per mL to 10 mg per mL.

28. (Original) The method of claim 27, wherein the digitalis glycoside is at a concentration of from 0.04 mg per mL to 5 mg per mL.

29. (Original) The method of claim 25 wherein the composition is administered to the subject intramuscularly, intravenously or subcutaneously.

30. (Original) The method of claim 25, wherein the composition is administered orally, intranasally, rectally or vaginally.

31. (New) The composition of claim 2, wherein the ratio by weight of digitalis glycoside to amorphous cyclodextrin is in the range of from 1:50 to 1:25.